The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. Longterm warfarin therapy is indicated in all patients with mechanical heart valves. However, it remains unclear whether these newer anticoagulants are as effective as warfarin for reducing thromboembolic complications among patients with mechanical heart valves. Over 252 patients were randomized to receive either dabigatran or warfarin at conventional target inr dosing when the study was terminated early for safety reasons. In the warfarin group, the time from initiation of anticoagulation to cardioversion was significantly longer than dabigatran median 67 vs. In patients with mechanical heart valves, anticoagulation with dabigatran was associated with significantly higher rates of stroke and major bleeding when compared to warfarin. The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit. Sep 15, 20 over 252 patients were randomized to receive either dabigatran or warfarin at conventional target inr dosing when the study was terminated early for safety reasons.
Dabigatran versus warfarin after mechanical mitral valve. The target inr for patients treated with warfarin is 2. Dabigatran etexilate in patients with mechanical heart. Anticoagulation management issues following mechanical cardiac valve replacement revolve around target levels for chronic oral anticoagulation. Dabigatran versus warfarin in patients with atrial fibrillation to the editor. No to dabigatran for mechanical heart valves cardiovascular. The american heart journal has published the design of the realign study, the first study to evaluate a novel oral anticoagulant as alternative to warfarin for use in patients with mechanical. A comparison of dabigatran etexilate with warfarin in.
Dec 11, 2014 realign was an investigational phase ii trial involving 252 patients, which compared dabigatran with warfarin in patients with recent mechanical heart valve replacement during the current. Methods in this phase 2 dosevalidation study, we studied two populations of patients. As oral anticoagulation is a mainstay of therapy in patients with mechanical. Dabigatran use in mechanical heart valve patients medscape. The patient population who underwent the valve replacement at the time of randomization and the population who had received the valve replacement more than three months earlier were both found to have excess. Dabigatran etexilate is contraindicated in patients with. We evaluated the use of dabigatran in patients with mechanical heart valves.
Warfarin is widely prescribed to reduce the risk of stroke in af, though food and drug interactions, the inconvenience of inr monitoring, difficulties of maintaining inr in a therapeutic range, and risk of hemorrhage are disadvantages to its use. Warfarin reduces risk of stroke in patients with mechanical heart valves but increases risk of hemorrhage and is difficult to use. In such patients, the data suggest that warfarin is more effective and safer than dabigatran. Aug 30, 2014 the introduction of the targetspecific oral anticoagulants tsoacs has led to a major shift in the management of patients at risk for thrombosis. However, warfarin medication increased the risk of hemorrhage.
Eikelboom jw, connolly sj, brueckmann m, et al realign investigators. The introduction of the targetspecific oral anticoagulants tsoacs has led to a major shift in the management of patients at risk for thrombosis. T1 dabigatran versus warfarin after mechanical mitral valve replacement in the swine model. Background dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. Warfarin, a vitamin k antagonist, has been the only oral anticoagulant used for prevention of thromboembolic complications in patients with mechanical heart valves. Despite this benefit, mhv demands lifelong anticoagulation with vitamin k antagonists vkas, most commonly warfarin, because of the high. Dabigatran versus warfarin in patients with mechanical heart valves article pdf available in new england journal of medicine 369.
I am a better safe than sorry type guy, so i wanted to make sure our patient community was on the same page specific to this new anticoagulant. The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with. Mechanical heart valve replacement is an absolute indication for anticoagulation. Ema dabigatran versus warfarin in patients with mechanical. Listing a study does not mean it has been evaluated by the u. Anticoagulation management in patients with atrial fibrillation and. The fdas announcement was preceded by a boehringer ingelheim press release detailing the contraindication. Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation. Rivaroxaban versus warfarin in patients with mechanical. The safety and efficacy of pradaxa in patients with bileaflet mechanical prosthetic heart. In realign, a phase 2 dosevalidation study, the investigators studied two populations of patients. Dabigatran in patients with mechanical heart valves n engl j med 369.
The american heart journal has published the design of the realign study, the first study to evaluate a novel oral anticoagulant as alternative to warfarin for use in patients with mechanical heart valves requiring anticoagulation therapy. Not only this, warfarin is a more difficult drug to use. Dabigatran versus warfarin in patients with mechanical heart valves against pro even though warfarin has shown to be effective over the years, the lifelong laboratory monitoring, restrictions on diet, cyp2c9 and vkorc1 polymorphisms, and drugdrug interactions put a burden on. All patients with major bleeding had pericardial bleeding. A study published in the new england journal of medicine noted that warfarin reduces the risk of stroke in patients with atrial fibrillation. A comparison between dabigatran and warfarin on time to. Based on these findings, patients with mechanical heart valves should be anticoagulated with warfarin, as opposed to dabigatran. The landscape continues to evolve as the evidence regarding their efficacy and safety in various clinical situations emerges. Sep 09, 2016 the dabigatran versus warfarin in patients with mechanical heart valves realign trial comparing dabigatran etexilate to warfarin was the only randomized controlled study in patient with mechanical valve prosthesis, but it was terminated prematurely because of an excess of thromboembolic and bleeding events among patients in the dabigatran group.
As oral anticoagulation is a mainstay of therapy in patients with. Dabigatran and other novel oral anticoagulants are effective and safe for reducing thromboembolic risk in the setting nonvalvular af. What is the effectiveness of dabigatran in patients with mechanical heart valves. Marie bussey january, 20 the fda recently released a drug safety communication indicating that dabigatran pradaxa should not be used in patients who have a mechanical prosthetic heart valve. Dabigatran versus warfarin for stroke prevention in. The safe and effective use of dabigatran and warfarin in. Role of novel anticoagulants for patients with mechanical. Apixaban versus warfarin for mechanical heart valve. Ive received several questions about the use of pradaxa as a potential coumadinsubstitute for patients with atrial fibrillation, valve disease andor mechanical heart valve replacements. Pdf dabigatran versus warfarin in patients with mechanical.
The patient population who underwent the valve replacement at the time of randomization and the population who had received the valve replacement more than three months earlier were both found to have excess risk of thromboembolic. These conditions include heart valve replacements, hip and knee joint replacements, hereditary blood clotting problems, or heart conditions like atrial fibrillation. One difference is that warfarin is approved for various conditions that lead to blood clots. Apixaban versus warfarin in patients with atrial fibrillation. Compare coumadin vs pradaxa headtohead with other drugs for uses, ratings, cost, side effects, interactions and more. Anticoagulation with otamixaban and ischemic events in nonstsegment elevation acute coronary 2. Dabigatran versus warfarin in patients with atrial fibrillation. Dabigatran versus warfarin in patients with mechanical heart valves. Management of anticoagulation in patients with mechanical heart.
Dabigatran pradaxa should not be used in mechanical heart. On the other hand, when one compares data from the 25% of warfarintreated patients with the poorest inr control inrs in range less than 53% of the time, then dabigatran appears to be considerably safer and more effective. Effective treatment with warfarin requires patients to be maintained. Dabigatran contraindicated for heart valves fritsma factor. A total of 30 patients 44% received warfarin and 38 patients 56% received dabigatran. Dabigatran pradaxa should not be used in mechanical. Dabigatran versus warfarin in patients with mechanical. Apr 10, 2011 ive received several questions about the use of pradaxa as a potential coumadinsubstitute for patients with atrial fibrillation, valve disease andor mechanical heart valve replacements.
In patients with mechanical heart valves and highrisk patients with prosthetic tissue valves, the addition of aspirin to warfarin therapy reduced mortality, particularly mortality from vascular. Dabigatran versus warfarin in patients with mechanical heart valves 2. Rivaroxaban versus warfarin in patients with mechanical heart valve. Amsterdam, the netherlands treatment with the oral anticoagulant dabigatran etexilate resulted in a higher number of thromboembolic and bleeding events compared to warfarin treatment in patients with mechanical heart valve replacements, according to results of the realign randomized, phase ii study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after. Dabigatran versus warfarin in patients with mechanical heart. Dabigatran is associated with increased risk of thromboembolic and bleeding events in patients with mechanical heart valves compared with warfarin. Dabigatran and warfarin have many different features. The effects of external electric currents on the heart. Nov 28, 20 dabigatran and other novel oral anticoagulants are effective and safe for reducing thromboembolic risk in the setting nonvalvular af. Dabigatran was found to be inferior to warfarin, both in terms of major bleeding and thromboembolic events. Dabigatran etexilate in patients with mechanical heart valves. Patients with mechanical heart valves are at a high risk of thromboembolic events. Warfarin coumadin or dabigatran pradaxa how do these.
Mechanical heart valves mhv are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. Regarding safety outcomes, there were seven major bleeding events in the dabigatran patients vs. According to the american heart association, atrial fibrillation af is estimated to affect more than 2. In this phase 2 dosevalidation study, we studied two populations of patients. Dabigatran versus warfarin in patients with atrial. Jun 20, 2012 the american heart journal has published the design of the realign study, the first study to evaluate a novel oral anticoagulant as alternative to warfarin for use in patients with mechanical. The dabigatran versus warfarin in patients with mechanical heart valves realign trial comparing dabigatran etexilate to warfarin was the only randomized controlled study in patient with mechanical valve prosthesis, but it was terminated prematurely because of an excess of thromboembolic and bleeding events among patients in the dabigatran group.
The aim of the realign randomised, phase ii study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement was to test a dosing regimen of dabigatranbased on the regimen used in relyin patients with bileaflet mechanical heart valves. Patients with mechanical valve replacement were randomly assigned in a 2. May 09, 2020 dabigatran pradaxa should not be used in mechanical heart valve patients henry i. Dabigatran pradaxa should not be used in mechanical heart valve patients henry i. Some patients with bioprosthetic heart valve replacements or mitral valve repair also may need anticoagulation. Dabigatran contraindicated for heart valves the fritsma. We would like to focus on the management in the warfarin group, which we think could have been even further optimized. Antithrombotic therapy for thromboprophylaxis in patients with mechanical heart valves is challenging. Realign was an investigational phase ii trial involving 252 patients, which compared dabigatran with warfarin in patients with recent mechanical heart valve replacement during the current. Zoll pm, paul mh, linenthal aj, norman lr, gibson w. The time to first bleed any bleeding was significantly shorter in the dabigatran group p 3 months before randomization, will be randomized between dabigatran etexilate or warfarin in a ratio of 2. Dabigatran unsuitable for use with mechanical heart valves. Sep 26, 20 all patients with major bleeding had pericardial bleeding. In this study, dabigatran was compared with warfarin in mechanical heart valve patients.
While these levels are important, they are only one aspect of a followup process that should be individualized to each patient with a mechanical cardiac valve and coupled with patient education, risk factor modification, and longterm followup. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves. Effectiveness of dabigatran etexilate for thromboprophylaxis. The fda s announcement was preceded by a boehringer ingelheim press release detailing the contraindication. Half of all peripheral intravenous lines in an australian tertiary emergency department are unused 4. Mechanical and bioprosthetic heart valves thrombosis canada. No data exist in the setting of mechanical heart valves. Eikelboom jw1, connolly sj, brueckmann m, granger cb, kappetein. This study evaluates the use of dabigatran in patients with mechanical heart valves. Marie bussey january, 20 the fda recently released a drug safety communication indicating that dabigatran pradaxa should not be used in. First study to evaluate alternative to warfarin for. Dabigatran etexilate in patients with mechanical heart valves realign the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Patients who received mechanical heart valves mhvs have significantly lower mortality, higher cumulative incidence of bleeding and, in some age groups, stroke than recipients of a biologic prosthesis.
1327 122 573 1143 141 717 1213 1263 1368 264 131 1338 164 417 1597 1572 1031 746 277 1378 160 832 244 522 1121 883 418 946 616 249 1189 716 1025 1280 730 981 1386 810 1098 18 429 304 951 405 809